Non-delusional pathological jealousy as an obsessive-compulsive spectrum disorder: Cognitive-behavioural conceptualization and some treatment suggestions

2012 ◽  
Vol 1 (3) ◽  
pp. 203-210 ◽  
Author(s):  
Willi Ecker
Keyword(s):  
Spectrum Disorder ◽  
Obsessive Compulsive ◽  
Cognitive Behavioural ◽  
Obsessive Compulsive Spectrum Disorder

Validation of a classification system of obsessive–compulsive spectrum disorder symptoms in a non-clinical sample

2011 ◽  
Vol 188 (1) ◽  
pp. 65-70 ◽  
Author(s):  
Michael L. Sulkowski ◽  
Twyla L. Mancil ◽  
Cary Jordan ◽  
Adam Reid ◽  
Elisa Chakoff ◽  
...  
Keyword(s):  
Classification System ◽  
Clinical Sample ◽  
Spectrum Disorder ◽  
Obsessive Compulsive ◽  
Obsessive Compulsive Spectrum Disorder

Preliminary assessment of obsessive–compulsive spectrum disorder scales for DSM-5

2013 ◽  
Vol 2 (2) ◽  
pp. 114-118 ◽  
Author(s):  
Richard T. LeBeau ◽  
Emily R. Mischel ◽  
Helen B. Simpson ◽  
David Mataix-Cols ◽  
Katherine A. Phillips ◽  
...  
Keyword(s):  
Spectrum Disorder ◽  
Preliminary Assessment ◽  
Obsessive Compulsive ◽  
Dsm 5 ◽  
Obsessive Compulsive Spectrum Disorder

scholarly journals Treatment of Hypochondriasis in Two Schizophrenia Patients Using Clozapine

2017 ◽  
Vol 2017 ◽  
pp. 1-3
Author(s):  
Antonio Tundo ◽  
Luca Proietti ◽  
Rocco de Filippis
Keyword(s):  
Therapeutic Strategy ◽  
Dosage Reduction ◽  
Treatment Options ◽  
Treatment Strategies ◽  
Mood Stabilizer ◽  
Behavioural Therapy ◽  
Obsessive Compulsive ◽  
Alternative Interventions ◽  
Cognitive Behavioural ◽  
Obsessive Compulsive Spectrum Disorder

Hypochondriasis (HYPO), an obsessive-compulsive spectrum disorder, is frequent in patients with schizophrenia (SCH) (20%), especially among those treated with clozapine (36.7%). Treatment options for OCS/OCD in patients under clozapine (CLZ) include combining clozapine with amisulpride/aripiprazole or a mood stabilizer, augmenting clozapine with a serotoninergic reuptake inhibitor, adding cognitive behavioural therapy, and gradually reducing dosage. No treatments have been proposed for HYPO in patients using clozapine so we examine these options in 2 cases and report the results. Among treatments delivered, only dosage reduction adequately worked. We recommend caution when thinking about escalating treatment and suggest trying it only when alternative interventions were not successful and weighing risk and benefits of this therapeutic strategy. Further research is needed to confirm the hypothesis that CLZ treatment induces hypochondriac symptoms, to investigate the prevalence of the phenomenon, and, mostly, to identify possible treatment strategies.

Sign in / Sign up

Export Citation Format

Share Document